BOSTON, MA — September 17, 2025 — Leads & Copy —
Akari Therapeutics, Plc (Nasdaq: AKTX) has filed a provisional patent application with the USPTO for its antibody drug conjugate (ADC) platform. The platform utilizes Akari’s spliceosome payload PH1 for treating cancer by modulating alternative splicing within cancer cells. The application represents a new patent family to further extend Akari’s proprietary position regarding its novel payload, PH1.
Abizer Gaslightwala, President and CEO of Akari Therapeutics, said the data in the application demonstrates advances in understanding spliceosome modulation and the potential of its PH1 payload to build first-in-class ADCs. He added that the company will continue to progress its research on its spliceosome modulating payload PH1 and present data and insights. The patent application increases the scope of its intellectual property estate and enables long term value creation for Akari and potential partners.
The application relates to how Akari’s PH1 payload modulates the spliceosome to disrupt alternative splicing drivers and the synthesis of proteins needed for cancer tumors to survive and grow. The company’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and delivers its novel PH1 payload directly into the tumor. AKTX-101 has shown significant activity and prolonged survival in preclinical studies and the potential to be synergistic with checkpoint inhibitors.
Investor Relations Contact:
JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com
Source: Akari Therapeutics
